Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs

被引:159
作者
Baker, EK
Johnstone, RW
Zalcberg, JR
El-Osta, A
机构
[1] Baker Med Res Inst, Alfred Med Res & Educ Project, Epigenet Human Hlth & Dis Lab, Prahran, Vic 3181, Australia
[2] Peter MacCallum Canc Ctr, Canc Immunol Program, Gene Regulat Lab, Melbourne 3002, Australia
[3] Peter MacCallum Canc Ctr, Dept Med Oncol & Haematol, Melbourne 3002, Australia
基金
英国惠康基金; 英国医学研究理事会;
关键词
cancer; chemotherapy; multidrug resistance; epigenetic modifications; chromatin;
D O I
10.1038/sj.onc.1208955
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mechanism of action of chemotherapeutic drugs and their ability to induce multidrug resistance (MDR) are of relevance to cancer treatment. Overexpression of P-glycoprotein (Pgp) encoded by the MDR1 gene following chemotherapy can severely limit the efficacy of anticancer agents; however, the manner by which cells acquire high levels of Pgp has not been defined. Herein, we demonstrate that chemotherapeutic drugs induce specific epigenetic modifications at the MDR1 locus, concomitant with MDR1 upregulation mediated by transcriptional activation, and a potential post-transcriptional component. We have established that the mechanisms are not mutually exclusive and are dependent on the methylation state of the MDR1 promoter. MDR1 upregulation did not result in further changes to the CpG methylation profile. However, dramatic changes in the temporal and spatial patterning of histone modi. cations occurred within the 50 hypomethylated region of MDR1, directly correlating with MDR1 upregulation. Specifically, drug-induced upregulation of MDR1 was associated with increases in H3 acetylation and induction of methylated H3K4 within discrete regions of the MDR1 locus. Our results demonstrate that chemotherapeutic drugs can actively induce epigenetic changes within the MDR1 promoter, and enhance the MDR phenotype.
引用
收藏
页码:8061 / 8075
页数:15
相关论文
共 53 条
  • [1] Abolhoda A, 1999, CLIN CANCER RES, V5, P3352
  • [2] Methylation of histone H3 Lys 4 in coding regions of active genes
    Bernstein, BE
    Humphrey, EL
    Erlich, RL
    Schneider, R
    Bouman, P
    Liu, JS
    Kouzarides, T
    Schreiber, SL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (13) : 8695 - 8700
  • [3] Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes
    Boggs, BA
    Cheung, P
    Heard, E
    Spector, DL
    Chinault, AC
    Allis, CD
    [J]. NATURE GENETICS, 2002, 30 (01) : 73 - 76
  • [4] CAMPOS L, 1992, BLOOD, V79, P473
  • [5] INDUCTION OF MULTIDRUG RESISTANCE IN HUMAN-CELLS BY TRANSIENT EXPOSURE TO DIFFERENT CHEMOTHERAPEUTIC DRUGS
    CHAUDHARY, PM
    RONINSON, IB
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (08) : 632 - 639
  • [6] Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase
    Chen, HW
    Lin, RJ
    Xie, W
    Wilpitz, D
    Evans, RM
    [J]. CELL, 1999, 98 (05) : 675 - 686
  • [7] Quantitative analysis of the hormone-induced hyperacetylation of histone H3 associated with the steroidogenic acute regulatory protein gene promoter
    Christenson, LK
    Stouffer, RL
    Strauss, JF
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) : 27392 - 27399
  • [8] Profiling methyl-CpG specific determinants on transcriptionally silent chromatin
    El-Osta, A
    Baker, EK
    Wolffe, AP
    [J]. MOLECULAR BIOLOGY REPORTS, 2001, 28 (04) : 209 - 215
  • [9] Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation
    El-Osta, A
    Kantharidis, P
    Zalcberg, JR
    Wolffe, AP
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (06) : 1844 - 1857
  • [10] FERGUSON PJ, 1988, CANCER RES, V48, P5956